B. Guillot

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière et al. · The Lancet · 1998 · 435 citations

Surgical Oncology, Detectable Node Metastases, Medicine +6

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld et al. · European Journal of Cancer · 2017 · 281 citations · Full text

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

Nicole Basset‐Séguin, Axel Hauschild, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 242 citations

Open-label Trial, Medicine, Pre-planned Interim Analysis +6

French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults

F. Amatore, A. Villani, M. Tauber et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 218 citations · Full text